Nifurtimox is under clinical development by Bayer and currently in Phase II for Refractory Medulloblastoma. According to GlobalData, Phase II drugs for Refractory Medulloblastoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nifurtimox LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nifurtimox is a nitrofuran derivative, acts as an antiprotozoal agent. It is formulated as tablets for oral route of administration. Lampit is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi.
Nifurtimox is under development for the treatment of relapsed or refractory neuroblastoma and medulloblastoma in combination with cyclophosphamide and topotecan.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Nifurtimox’s drug-specific PTSR and LoA scores, buy the report here.